C25006 (R/R)
A Phase 4, Open-label, Single-Arm Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
Study Treatments
Brentuximab vedotin IV on day 1 (21-day cycle; max 16 cycles)
Inclusion criteria
- 18 years or older
- Relapsed or refractory systemic Anaplastic Large Cell Lymphoma (sALCL) who have previously received at least 1 multiagent chemotherapy
- Bidimensional measurable disease
- ECOG 0-1
Exclusion criteria
- Previous treatment with brentuximab vedotin
- Previously received an allogeneic transplant
- Patients with current diagnosis of primary cutaneous ALCL (patients whose ALCL has transformed to sALCL are eligible)
Participating sites
- Cliniques Universitaires UCL Saint Luc
- ZNA Stuivenberg
- UZ Leuven
- UZ Gent